Amarillo Biosciences, Inc. Stock Other OTC
Equities
AMAR
US02301P2056
Biotechnology & Medical Research
Financials (USD)
Sales 2022 | 3.52M | Sales 2023 | 122K | Capitalization | 8.32M |
---|---|---|---|---|---|
Net income 2022 | -14M | Net income 2023 | -13M | EV / Sales 2022 | 3.36 x |
Net cash position 2022 | 585K | Net Debt 2023 | 3.81M | EV / Sales 2023 | 99.3 x |
P/E ratio 2022 |
-0.6
x | P/E ratio 2023 |
-0.61
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 39.12% |
Managers | Title | Age | Since |
---|---|---|---|
Chun Hsien Tsai
CEO | Chief Executive Officer | 54 | 21-04-14 |
Lawrence Lin
COO | Chief Operating Officer | 55 | 21-07-31 |
Shu Ying Pan
SAM | Sales & Marketing | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Yao Chung Chiang
BRD | Director/Board Member | 70 | 21-04-14 |
Pao Sheng Wei
BRD | Director/Board Member | 66 | 22-06-14 |
Chung Yi Tsai
BRD | Director/Board Member | 47 | 21-04-14 |
1st Jan change | Capi. | |
---|---|---|
+20.12% | 126B | |
+25.25% | 119B | |
+25.56% | 27.95B | |
-19.51% | 20.5B | |
-14.36% | 17.12B | |
-15.63% | 16.1B | |
-46.67% | 14.97B | |
+11.89% | 14.84B | |
+57.74% | 14.38B |